TOKYO -- Japanese drugmaker Shionogi will begin a Phase 3 clinical trial on its COVID-19 vaccine this month, mainly in Vietnam and other Asian countries, CEO Isao Teshirogi said Monday.
The clinical trial, which will involve two groups, one given the actual vaccine and the other given a placebo, is aimed at putting its "recombinant protein vaccine" on the list of the World Health Organization-approved vaccines, Teshirogi said at a news conference to discuss the company's earnings. Shionogi is the front-runner in COVID vaccine development in Japan,
